Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Statistical Hypothesis Testing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Statistical Hypothesis Testing. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-000319-41 Sponsor Protocol Number: RPC01-3101 Start Date*: 2015-09-18
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
    Medical condition: ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) NL (Completed) GB (Completed) BE (Completed) BG (Completed) PL (Completed) HR (Completed) LV (Completed) AT (Completed) GR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003197-26 Sponsor Protocol Number: IOM-120 Start Date*: 2008-05-29
    Sponsor Name:BRACCO IMAGING
    Full Title: Studio randomizzato di fase IV, doppio cieco, multicentrico, per il confronto di Iomeron 400 con Visipaque 320 nell'angiografia coronarica con Tomografia Computerizzata a doppio tubo (DS-CTA)
    Medical condition: CAD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001319-36 Sponsor Protocol Number: FIERCE-21(B-701-U21) Start Date*: 2017-08-23
    Sponsor Name:BioClin Therapeutics, Inc.
    Full Title: A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After,...
    Medical condition: Treatment of progressed or refractory metastatic UCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022110-29 Sponsor Protocol Number: SG006 Start Date*: 2010-10-08
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in...
    Medical condition: Prevention or attenuation of COPD symptoms caused by respiratory viruses
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000444-84 Sponsor Protocol Number: EMR62225-030 Start Date*: 2005-06-22
    Sponsor Name:Merck KGaA
    Full Title: An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from...
    Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004215-30 Sponsor Protocol Number: BRD/05/155 Start Date*: 2006-02-24
    Sponsor Name:Joint Sponsorship: University College London (UCL) & University College London Hospitals (UCLH)
    Full Title: Imaging the neural correlates of cholinergic and behaviour driven rehabilitation in patients with Wernicke’s aphasia: a double-blinded, cross-over, randomised controlled trial.
    Medical condition: Wernicke's aphasia caused by a stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004340-11 Sponsor Protocol Number: 17403 Start Date*: 2018-06-13
    Sponsor Name:Bayer AG
    Full Title: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or me...
    Medical condition: mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed) CZ (Completed) ES (Completed) PT (Completed) FI (Completed) SK (Completed) HU (Completed) DK (Completed) BE (Completed) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004973-83 Sponsor Protocol Number: S154.3.021 Start Date*: 2007-05-02
    Sponsor Name:Solvay Pharmaceuticals. Inc.
    Full Title: A Randomized, Multicenter, Double-blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients.
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020069-26 Sponsor Protocol Number: DMD114044 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy.
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) IT (Completed) PL (Completed) CZ (Completed) ES (Completed) NO (Completed) DK (Completed) HU (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-005006-35 Sponsor Protocol Number: RM-493-022 Start Date*: 2018-05-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto...
    Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) ES (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001432-13 Sponsor Protocol Number: MRZ 92579/TI/3004 Start Date*: 2008-10-20
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus
    Medical condition: Long-term safety, tolerability and efficacy of Neramexane in Patients with subjective Tinnitus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042398 Subjective tinnitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) FR (Completed) PT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003934-25 Sponsor Protocol Number: 3475-412 Start Date*: 2017-03-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous...
    Medical condition: Locally advanced head and neck squamous cell carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) AT (Ongoing) PL (Ongoing) CZ (Ongoing) BE (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006253-29 Sponsor Protocol Number: CLI00070 Start Date*: 2012-07-31
    Sponsor Name:Cerus Corporation
    Full Title: A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S-303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
    Medical condition: Acute anemia secondary to cardiovascular surgery.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10054312 Anemia postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005047-28 Sponsor Protocol Number: CS0011-A-U301 Start Date*: 2007-03-23
    Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS
    Medical condition: The current study will support an indication for rivoglitazone as oral monotherapy to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with diet and exer...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LV (Completed) SK (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001638-27 Sponsor Protocol Number: FFP104-001 Start Date*: 2014-10-15
    Sponsor Name:Fast Forward Pharmaceuticals, B.V.
    Full Title: A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed with Primary Biliary Cirrhosi...
    Medical condition: Primary Biliary Cirrhosis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018329-20 Sponsor Protocol Number: LN-LAQ-201 Start Date*: 2010-05-07
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combinati...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025140 Lupus nephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000311-25 Sponsor Protocol Number: BAY86-9766/16553 Start Date*: 2013-10-17
    Sponsor Name:Bayer Healthcare AG
    Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)
    Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000241-39 Sponsor Protocol Number: BAY86-9766/16728 Start Date*: 2013-07-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato...
    Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002609-31 Sponsor Protocol Number: ISO-44-013 Start Date*: 2012-01-27
    Sponsor Name:Guerbet
    Full Title: Diagnostic contribution of XENETIX® CT PERFUSION in pre-therapeutical assessment of hepatocellular carcinoma.
    Medical condition: Subjects diagnosed for HCC and planned for surgery (tumorectomy, sectionectomy, segmentectomy, lobectomy or transplantation).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001462-17 Sponsor Protocol Number: WSG-AM06 Start Date*: 2012-03-29
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
    Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA